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Summary Rhizoxin is a new anti-tumour agent isolated from the pathogenic fungus Rhizopus chinensis. It has
shown broad activity against murine tumour models and is also active against vinca alkaloid-resistant cells. The
purpose of our studies was to determine the clinical activity of this compound in patients with advanced breast
cancer and melanoma. Based on the results of a phase I study, 2.0 mg m-2 was administered as intravenous
infusion over 5 min every 21 days. Nineteen patients were entered into the breast cancer phase II trial and
received a total of 50 courses (median 2, range 1-6). Ofthese, dose reductions were performed in three courses
because of leucopenia or stomatitis (1.5 mg m-2, one course; 1.45 mg m-2, two courses). Twenty-six patients
were entered into the melanoma trial and received a total of 70 courses (median 2, range 1-12). No dose
reductions were required. All patients were eligible for toxicity. Haematological toxicity included neutropenia
CTC grade 3 (29/120 courses, 24.2%) and grade 4 (11/20 courses, 9.2%). Only drug-related CTC grade 1
thrombocytopenia was observed. Non-haematological toxicity included alopecia in all patients after two
courses of treatment as well as CTC grade 3/4 stomatitis and asthenia. In the breast cancer study, one patient
achieved a more than 50% tumour reduction after six cycles but was progressing after 6 weeks. Another patient
showed a partial remission after the first course but was taken off the study because of CTC grade 3 skin
toxicity. One patient was not evaluable for response (early death). No objective remissions were observed in 15
evaluable patients. In melanoma, no objective remissions were observed. We conclude that rhizoxin can be
safely administered at 2.0 mg m-2 every 3 weeks. However, it has little activity in patients with advanced
breast cancer and melanoma.
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Rhizoxin (NSC 332.598; E 87/010) is a macrocyclic lactone
antibiotic with antifungal and antineoplastic activity isolated
from the pathogenic fungus Rhizopus chinensis (Iwasaki et al.,
1984, 1986; Tsuruo et al., 1986). A recognised mechanism of
action for rhizoxin includes binding to the tubulin #-chain at
a site that is different from the vinblastine or colchicine
binding sites but apparently identical with the binding site of
maytansin (Takahashi et al., 1987a, 1989; Bai et al., 1990;
Hamel, 1992). Subsequently, polymerisation of tubulin is
effectively inhibited and depolymerisation of microtubuli
promoted (Takahashi et al., 1987b). By this mechanism,
rhizoxin inhibits mitosis and lacks cross-resistance with
vincristine or vinblastine (Otake, 1988). Rhizoxin has shown
promising anti-tumour activity in a variety of experimental
models in vitro and in vivo, including murine leukaemias,
melanoma, sarcoma, breast, non-small and small-cell lung,
colon and renal cancers (Kiyoto et al., 1986; Hendriks et al.,
1992; Takigawa et al., 1993). One clinical phase I trial has
been completed and has shown a maximal tolerated dose of
2.6 mg m-2 when the agent was administered as intravenous
infusion over 5 min repeated every 3 weeks. Dose-limiting
toxicities were mucositis, diarrhoea, and myelotoxicity. Other
side-effects included malaise and phlebitis at the injection site.
Minor tumour regressions were seen in two patients with
advanced breast cancer in one phase I trial. The
recommended dose with this schedule was 2.0 mg m-2
(Bissett et al., 1992; Graham et al., 1992).
In view of the preclinical data indicating the potential for
broad-spectrum activity, a co-ordinated phase II programme
studying a number of tumor types was planned, involving the
Cancer Research Campaign in the UK and the Early Clinical
Trials Group (ECTG) of the EORTC. Within the ECTG, the
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studies were designed to determine whether partial or
complete remissions could be achieved with rhizoxin in
advanced breast cancer and melanoma and to determine their
duration. In addition, assessment of the probability of an
actual response rate and a more detailed characterisation of
rhizoxin-related toxicities were intended.
Patients and methods
Patients
Eligibility criteria for both studies included: histologically or
cytologically confirmed disease; at least one bidimensionally
measurable lesion; age >18 years; adequate bone marrow
function (leucocytes >4000 pl-', platelets > 100 000 ,ul'-);
adequate renal function (serum creatinine < 140 jmol 1-l or
creatinine clearance >60 ml min-'; adequate liver function
(serum bilirubin <26 4umol I-1; SGPT and SGOT < three
times the upper limit of normal); WHO performance status
<2; estimated life expectancy >3 months; no symptomatic
brain or leptomeningeal disease; no other malignancies
(exception: adequately treated cone-biopsied in situ carcino-
ma of the cervic uteri, basal or squamous cell carcinoma of
the skin); no uncontrolled infection or other serious medical
contidions; informed consent according to institutional
guidelines. Pregnant or lactating females were not eligible
for this study. Specific additional entry criteria for breast
cancer patients were: not more than one prior chemotherapy
regimen for advanced disease; discontinuation of chemother-
apy or hormonal or radiation therapy at least 4 weeks before
study entry (6 weeks in the case of prior mitomycin C or
nitrosoureas. Specific additional entry criteria for melanoma
patients were: no prior chemotherapy (exception adjuvant,
local/extracorporal chemotherapy); prior immunotherapy
with interleukin 2, interferon or other biological response
modifiers was allowed.Phase 11 studies with rhizoxin in breast cancer and melanoma
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Treatment
Rhizoxin was provided as lyophylisate by Fujisawa
Pharmaceutical, Kashima, Japan. Immediately before use,
the compound was reconstituted with a solution of 80% (v/v)
propylene glycol and 20% (v/v) ethanol followed by water for
injection to give a final concentration of 1 mg ml-' rhizoxin,
40% (v/v) propylene glycol, 10% (v/v) ethanol. Aliquots of
2 mg m-2 of this solution were administered as intravenous
infusion over 5 min repeated every 3 weeks. Doses of
subsequent courses were adjusted according to toxicity. No
dose escalation was planned. Treatment delay of more than 1
week, thrombocytopenic haemorrhage or febrile neutropenia
requiring hospitilisation or non-haematologic toxicities great-
er than or equal to grade 3 resulted in a 25% dose reduction.
Patients were treated until disease progression or unaccep-
table toxicity. For evaluation of response, patients had to
receive at least two courses of therapy. Patients progressing
after the first cycle were classified as early progression.
Standard WHO criteria were applied for evaluation of
response, NCI Common Toxicity Criteria were used for the
grading of toxicities.
Results
Patients
A total of 45 eligible patients were entered into two clinical
phase II studies (melanoma: 26, breast: 19). Table I
summarises the patients' characteristics. Two breast cancer
patients entered were ineligible. One patient presented with
liver metastases of less than 2.5 cm and the other patient had
received two prior regimens for advanced disease. A total of
120 courses were administered. Breast cancer patients
received a median of two courses with a range of 1-6.
Melanoma patients received a median of two courses with a
range of 1-12. Dose reductions were required in only three
courses (all breast cancer patients). In these courses, doses
were reduced by 25% owing to toxicity (haematologic and
mucositis).
Toxicities
Myelosuppression was the predominant type of toxicity with
CTC grade 3 or grade 4 occurring in approximately one-third
ofcourses (Table II). One event of grade 4 thrombocytopenia
was unrelated to treatment. This patient subsequently
developed disease-related disseminated intravascular coagula-
tion syndrome. Another event of grade 4 thrombocytopenia
was considered treatment-related. Non-haematological toxi-
cities are summarised in Table III. Alopecia was complete
and almost universal after two courses of treatment. Nausea
and vomiting were infrequent and mild.
Response
Of 19 patients entered into the breast cancer study, two were
considered not evaluable for response and two not eligible.
However, ofthese, one patient showed a partial reponse after
the first treatment but had to be taken off the study owing to
grade 3 skin toxicity, including a bullous exanthema
involving the trunk, neck and arms. The patient received
further treatment with the CMF regimen. A second patient
was inevaluable for response due to early death. One patient
had a partial response after six courses but was found to be
progressive 6 weeks later. This patient was classified as
having an overall response of 'no change'. Six additional
patients were classified as 'no change' (median duration 12
weeks, range 12-16+ weeks) and eight patients had
progressive disease. Therefore no formal objective remissions
(95% CI: 0-22%) were seen in the 15 evaluable patients.
In the melanoma study, two patients were not evaluable
for response, both were lost to follow-up after one and two
cycles respectively. Four patients had 'no change' (median
duration 12 weeks, range 6-36 weeks). Twenty patients were
Table I Patients' characteristics
No. ofpatients
Parameter Breast cancer Melanoma
No. of eligable patients 19 26
Male/female 0/17 16/10
Age (years) median (range) 56 (34-72) 54 (24-76)
Performance status (WHO)
0 7 15
1 7 9
2 3 2
Prior therapy
Surgery 17 26
Chemotherapy 16 2
Immunotherapy 3 0
Hormonal therapy 15 1
Radiation 15 4
Table II Treatment-related haematological toxicities per course
(n= 120cycles)
NCI CTC grade
Parameter 1 2 3 4 Z (%)
Leucopenia 28 36 8 3 75 (63)
Neutropenia 17 16 29 11 73 (61)
Anaemia 40 7 1 0 48 (40)
Thrombyocytopenia 5 0 0 1 6 (5)
Table ITI Treatment-related haematological toxicities per course
(n= 123cycles)
NCI CTC grade
Parameter 1 2 3 4 Z (%)
Alopecia 25 79 - - 104 (85)
Asthenia 30 11 2 1 44 (36)
Stomatitis 13 23 2 1 39 (32)
Skin 12 16 2 0 30 (24)
Nausea 23 3 1 0 27 (20)
Allergy 7 14 0 0 21 (17)
Diarrhoea 15 4 0 0 19 (15)
Local 10 7 - - 17 (14)
Vomiting 12 2 0 0 14 (11)
Fever 6 6 0 0 12 (10)
Infection 2 6 2 0 10 (8)
Liver 7 2 0 0 9 (7)
progressing while on treatment, including three patients with
early progression. One patient was registered but as a result
of rapid disease progression did not receive treatment with
rhizoxin.
Discussion
This report summarises two phase II studies with the new,
tubulin-targeting agent rhizoxin that were conducted in
patients with advanced breast cancer and melanoma.
Although minor responses were observed in two breast
cancer patients in a clinical phase I study with rhizoxin, our
results indicate only marginal activity of this compound in
advanced breast cancer (Bissett et al., 1992). Of interest is,
however, that both patients in the current studies had not
received extensive prior treatment. One patient had achieved
a partial response after four cycles of CMF 38 months before
receiving rhizoxin. The other patient had only received
hormonal and radiation therapy. All patients with 'no
change' after rhizoxin had received prior anthrycycline-
containing regimens. Also, 9 of 12 patients with progressive
disease after rhizoxin had received prior anthracycline-
containing regimens. These data indicate that chemonaive
patients may be more sensitive to rhizoxin than pretreated
patients and that further studies in minimally pretreatedPhase 11 studies with rhizoxin in breast cancer and melanoma
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patients may be warranted. In the melanoma study no
objective remissions or even short-lasting tumour regressions
were noted. This indicates that rhizoxin is inactive against
this tumour type, despite its activity in preclinical melanoma
models. Similar results were obtained in phase II trials
conducted by CRC in colon, renal and ovarian cancer (Kerr
et al., 1995). Further studies of this class of agents will
depend on the identification of more effective analogues in
preclinical models.
Haematological toxicities during these phase II studies
were acceptable. The leading side-effect was neutropenia,
which was accompanied by fever of unknown origin and
infection in a total of four patients. In accordance with the
observation of a previous phase I study, non-haematological
toxicities mainly consisted of stomatitis and asthenia.
However, a variety of other, less severe toxicities were
causally related to treatment with rhizoxin, including
alopecia, skin reactions, local phlebitis at the site of injection
and gastrointestinal symptoms.
We conclude that the administration of rhizoxin at
2.0 mg m-2 as intravenous bolus every 3 weeks is feasible
and safe. However, clinical activity of this agent against
advanced breast cancer is lacking. In addition, rhizoxin is
clinically inactive against advanced melanoma.
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